GlassScriptPhysician profile
Karim T Attia
NPI 1801139217
$42,617.17
in general payments reported to CMS, 2019-2025
15 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.50 · 2020: $13.53 · 2022: $24.96 · 2023: $156 · 2024: $20K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $1,615 · Travel and Lodging: $670 · Education: $12.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,225.00 |
| Food and Beverage | $1,615.18 |
| Travel and Lodging | $670.29 |
| Education | $12.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29,830.49 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $12,395.00 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $139.18 | 2024-2025 | Tarpeyo |
| Akebia Therapeutics INC | $50.72 | 2024-2025 | Vafseo |
| Pfizer INC. | $31.12 | 2019 | |
| Genzyme Corporation | $24.96 | 2022 | |
| Novo Nordisk INC | $22.73 | 2025 | Ozempic |
| Amgen INC. | $20.93 | 2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $18.66 | 2024 | |
| Vifor Pharma, INC. | $17.42 | 2025 | Veltassa |
| Glaxosmithkline, LLC. | $15.34 | 2023 | Benlysta |
| Nxstage Medical, INC. | $13.53 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.06 | 2019 | |
| Travere Therapeutics, INC. | $12.71 | 2024-2025 | Filspari |
| Allergan, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Attia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.